UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77
UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.
Read original at benzingaStocks · News reference
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100
Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 4:02 PM
- Checked
- Aug 5, 2026, 4:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why TransMedics Stock Is Sinking Today
TransMedics stock fell 8% after Q2 earnings showed 21% sales growth but adjusted net income dropped more than 50% due to reinvestment in new kidney organ care systems and manufacturing. Despite the decline, the analyst remains bullish on the stock, citing upcoming clinical trials for heart and lung systems, a new kidney OCS in development, and European expansion opportunities.
Read original at the-motley-foolSpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.
Read original at benzinga